Pricing Log in Create free account

SAB Biotherapeutics, Inc. (SABS) vs Sol-Gel Technologies Ltd. (SLGL)

SAB Biotherapeutics, Inc. and Sol-Gel Technologies Ltd. are both Biotechnology companies. SAB Biotherapeutics, Inc. and Sol-Gel Technologies Ltd. are of similar size ($235.7M and $224.9M). SAB Biotherapeutics, Inc. grew revenue faster over the last twelve months: −60.3% against −92.5%. SAB Biotherapeutics, Inc. has the higher net margin (0.00% vs −910.1%) and the higher return on invested capital (−39.0% vs −6,630.2%). Across the 17 metrics below, SAB Biotherapeutics, Inc. leads on 11 and Sol-Gel Technologies Ltd. on 6.

Valuation

Metric SABS SLGL Biotechnology median
P/E n/m n/m 8.50
P/S 123.99 117.08 9.71
P/B 0.94 4.37 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales 62.79 126.78 9.21
Earnings yield (25.30%) (8.78%) (33.15%)
Free cash flow yield (28.47%) (10.12%) (25.50%)

Profitability

Metric SABS SLGL Biotechnology median
Gross margin 100.00% 100.00% 65.16%
Operating margin 0.00% (986.96%) 0.00%
Net margin 0.00% (910.14%) 0.00%
Free cash flow margin 0.00% (1,185.18%) 0.00%
Return on equity (19.21%) (40.85%) (56.36%)
Return on assets (16.24%) (35.11%) (48.04%)
Return on invested capital (38.97%) (6,630.24%) 0.00%

Growth

Metric SABS SLGL Biotechnology median
Revenue growth (TTM) (60.26%) (92.50%) 6.02%
EPS growth (last fiscal year) 78.53% 42.37% 30.26%
Revenue growth, 5-year CAGR — 17.19% 9.41%
Net income growth, 5-year CAGR (26.69%) 0.00% 0.00%

Health

Metric SABS SLGL Biotechnology median
Debt to equity 0.01 0.00 0.00
Current ratio 9.22 10.37 4.72
Net debt to EBITDA 2.03 3.23 0.96

Dividend

Metric SABS SLGL Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric SABS SLGL Biotechnology median
Market cap 235.66m 224.92m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack